Literature DB >> 17493232

Low Gleason score prostatic adenocarcinomas are no longer viable entities.

D M Berney1.   

Abstract

Gleason scoring is the most powerful predictor of the behaviour of prostatic adenocarcinoma. It was devised more than 30 years ago and is used by pathologists worldwide. However, advances in immunochemistry and the understanding of the biological potential of some tumours have made the diagnosis of tumours of grades 1 and 2, and hence low score (2-4), a rarity. It is suggested that Gleason score 2(1 + 1) tumours, if they do exist, are so rare and so benign that they are a redundant entity and should not be identified as a malignancy. Similar problems revolve around the diagnosis of Gleason score 4(2 + 2) tumours and the criteria for their diagnosis are difficult to evaluate and revolve around reference to the score 2(1 + 1) lesion. The continued presence of low-grade tumours in the Gleason grading system leads to diagnostic confusion, potential error and, more importantly, confusion for patients diagnosed with score 6(3 + 3) tumours. I suggest that Gleason grade 1 (and therefore scores of 2 and 3) should be removed from the Gleason grading system. Gleason grade 2 (and therefore score 4 and 5) tumours require serious re-evaluation if they are to remain clinically useful diagnoses.

Entities:  

Mesh:

Year:  2007        PMID: 17493232     DOI: 10.1111/j.1365-2559.2007.02596.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Current perspectives on Gleason grading of prostate cancer.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

2.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

3.  Perinucleolar compartment prevalence is a phenotypic pancancer marker of malignancy.

Authors:  John T Norton; Callie B Pollock; Chen Wang; Julian C Schink; J Julie Kim; Sui Huang
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

4.  Pseudolumen size and perimeter in prostate cancer: correlation with patient outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; M Scott Lucia
Journal:  Prostate Cancer       Date:  2011-07-14

5.  YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells.

Authors:  Xia Sheng; Wen-Bin Li; De-Lin Wang; Ke-Hong Chen; Jian-Jia Cao; Zhao Luo; Jiang He; Mei-Cai Li; Wu-Jiang Liu; Chao Yu
Journal:  Mol Med Rep       Date:  2015-06-29       Impact factor: 2.952

6.  Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.

Authors:  Daniel M Berney; Luis Beltran; Gabrielle Fisher; Bernard V North; David Greenberg; Henrik Møller; Geraldine Soosay; Peter Scardino; Jack Cuzick
Journal:  Br J Cancer       Date:  2016-04-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.